Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 160

Sort by

Sort Order Select

Journal Articles

Pharmacokinetics of Extended Half-Life Factor VIII Products By myPKFiT R Is Useful for Personalized Treatment in Children with Severe Hemophilia a

Risa Matsumura, Keita Tomioka, MD, Shiho Nishimura, MD, Yoko Mizoguchi, MD PhD, Hiroshi Kawaguchi, MD PhD, Masao Kobayashi, MD PhD

Blood (2019) 134 (Supplement_1): 1127.

https://doi.org/10.1182/blood-2019-128149

Published: 2019

Journal Articles

Quantitative Measurements of Hemophilic Joint Tissues By Point-of-Care Musculoskeletal Ultrasound Are Associated with Clinical and Functional Joint Outcome Parameters

Akram Mesleh Shayeb, MD, Richard Barnes, PhD MPH, Cris Hanacek, BS, Andres Flores, MS, ATC, CES, Rebecca Kruse-Jarres, MDMPH, Bruno Steiner, PT, DPT, LMT, RMSK, Doris Quon, MD PhD, Cindy Bailey, DPT, OCS, SCS, ATC, Annette von Drygalski, MD PharmD

Blood (2019) 134 (Supplement_1): 905.

https://doi.org/10.1182/blood-2019-129690

Published: 2019

Journal Articles

Correcting Rare Blood Disorders Using Coagulation Factors Produced In Vivo By Shielded Living Therapeutics TM Products

Guillaume Carmona, PhD, Lauren Barney, PhD, Jared Sewell, PhD, Ryan Newman, Christine Carroll, Michael Beauregard, Janet Huang, MSc, Richard W Heidebrecht, Jr., PhD, Deya Corzo, MD, David Moller, MD, Devyn Smith, PhD, David Peritt, PhD, Rogerio Vivaldi, MD MBA

Blood (2019) 134 (Supplement_1): 2065.

https://doi.org/10.1182/blood-2019-127050

Published: 2019

Journal Articles

Cost-Effectiveness Model of Recombinant FVIII Versus Emicizumab Treatment of Patients With Severe Hemophilia A Without Inhibitors

Shawn X. Sun, Yanyu Wu, Michael McDermott, Marjolijn van Keep

Blood (2019) 134 (Supplement_1): 2102.

https://doi.org/10.1182/blood-2019-124421

Published: 2019

Journal Articles

Prophylactic Treatment in People with Severe Hemophilia B in the US: An Analysis of Real-World Healthcare System Costs and Clinical Outcomes

Declan Noone, MSc, Gabriel Pedra, PhD, Sohaib Asghar, MSc, Jamie O'Hara, MSc, Eileen K Sawyer, PhD, Nanxin (Nick) Li, PhD

Blood (2019) 134 (Supplement_1): 2118.

https://doi.org/10.1182/blood-2019-126576

Published: 2019

Journal Articles

Correlations between von Willebrand Factor Antigen Levels and Factor VIII Pharmacokinetics Are Similar across Different FVIII Products in Patients with Severe Hemophilia A

Alfonso Iorio, Monika Maas Enriquez, Heinz Delesen, Alexander Solms, Stacy E. Croteau, Erik Berntorp

Blood (2019) 134 (Supplement_1): 3637.

https://doi.org/10.1182/blood-2019-127046

Published: 2019

Journal Articles

Non-Canonical MYD88/TIRAP-Dependent Anti-Inflammatory Function of Pro-Coagulant Factor VIII

Sandra Mignot, Sandrine Delignat, PhD, Sebastien Lacroix-demaze, PhD, Christine Bole-Feysot, PhD, Sherine Tei, Ananthy Kiddinan, Olivier Hermine, MD PhD, Laurent Frenzel, MD PhD

Blood (2019) 134 (Supplement_1): 3638.

https://doi.org/10.1182/blood-2019-127504

Published: 2019

Journal Articles

Combined Point of Care Tools Are Able to Improve Treatment Adherence and Health-Related Quality of Life in Patients with Severe Hemophilia: An Observational Prospective Study

Mariasanta Napolitano, Simona Raso, MD, Maria Francesca Mansueto, PhD, Salvatrice Mancuso, MD, Matteo Nicola Dario Di Minno, MD PhD, Dalila Scaturro, MD, Giulia Letizia Mauro, Prof,MD, Giovanni Di Minno, Sergio Siragusa, Prof, MD

Blood (2019) 134 (Supplement_1): 3455.

https://doi.org/10.1182/blood-2019-128129

Published: 2019

Journal Articles

EPCR Deficiency Prevents Development of Hemophilic Arthropathy

Jhansi Magisetty, PhD MSc, Usha Pendurthi, PhD, Charles T. Esmon, PhD, L. Vijaya Mohan Rao, PhD

Blood (2019) 134 (Supplement_1): 159.

https://doi.org/10.1182/blood-2019-124972

Published: 2019

Journal Articles

Clinical Study to Investigate the Efficacy and Safety of Wilate during Prophylaxis in Previously Treated Patients with Von Willebrand Disease (VWD)

Robert F. Sidonio, Jr., MD MSc, Bruce A. Schwartz, PhD

Blood (2019) 134 (Supplement_1): 4931.

https://doi.org/10.1182/blood-2019-128339

Published: 2019

Journal Articles

Characteristics of Hemophilia A Patients Treated with Emicizumab: an Early View using Claims Database Analysis

Arash Mahajerin, MD MS, Erru Yang, MS, Anisha M. Patel, PhD

Blood (2019) 134 (Supplement_1): 4928.

https://doi.org/10.1182/blood-2019-123724

Published: 2019

Journal Articles

Innate Immune Mechanism of Hemarthrosis in Hemophilia-a Mice

Tomasz W. Kaminski, PharmD, Egemen Tutuncuoglu, MSc, Margaret V. Ragni, MD MPH, Mark T Gladwin, MD, Prithu Sundd, PhD

Blood (2019) 134 (Supplement_1): 1043.

https://doi.org/10.1182/blood-2019-130471

Published: 2019

Journal Articles

Low-Grade Inflammation in Hemophilia

Lynn M Knowles, PhD, Hermann Eichler, Jan Pilch, MD

Blood (2019) 134 (Supplement_1): 1115.

https://doi.org/10.1182/blood-2019-125127

Published: 2019

Journal Articles

Estimating the Burden of Intracranial Hemorrhage in Persons with Hemophilia A using Administrative Claims Data

Arash Mahajerin, MD MS, Anisha M. Patel, PhD, Erru Yang, MS, Chinelo C. Orji, MS, Richard H. Ko, MD

Blood (2019) 134 (Supplement_1): 2398.

https://doi.org/10.1182/blood-2019-123713

Published: 2019

Journal Articles

New therapies for hemophilia

Angela C. Weyand, Steven W. Pipe

Blood (2019) 133 (5): 389–398.

https://doi.org/10.1182/blood-2018-08-872291

Published: 2019

Journal Articles

Thrombin Generation As a Promising Biomarker for the Prediction of Bleeding Phenotype in Patients with Non-Severe Hemophilia

Fadi Nossair, MD, Nina Hwang, Vanessa Salinas, MD, Nicole Crook, RN, Jacqueline Limjoco, BSN BA RN, Diane J. Nugent, MD, Courtney D. Thornburg, MD

Blood (2018) 132 (Supplement 1): 3788.

https://doi.org/10.1182/blood-2018-99-119198

Published: 2018

Journal Articles

Adding Slow Release Tetracosactide Acetate to Eltrombopag Improves Haematological Response in ITP Patients with Platelet-Count Fluctuation

Francesco Iuliano, MD, Eleonora Iuliano, MD, Marco Rossi, MD

Blood (2018) 132 (Supplement 1): 2449.

https://doi.org/10.1182/blood-2018-99-118518

Published: 2018

Journal Articles

Changing the Paradigm in Hemophilia Care: Extended Half-Life Products (rFVIIIFc and rFIXFc)

Louis M. Aledort, MD, Nisha Jain, MBBS,MD, Nanxin Li, Sangeeta Krishnan, PharmD, Benjamin Hagberg, Jun Su, MD

Blood (2018) 132 (Supplement 1): 3514.

https://doi.org/10.1182/blood-2018-99-114905

Published: 2018

Journal Articles

Surveillance of Hemophilia in Indiana: A Preliminary Report

Amanda Okolo, MPH, John M Soucie, PhD, Scott D. Grosse, PhD, Chris Roberson, JD, MPH, Isaac Janson, PhD, Martha Allen, MSN, Amy Shapiro

Blood (2018) 132 (Supplement 1): 3516.

https://doi.org/10.1182/blood-2018-99-118849

Published: 2018

Journal Articles

Early Prophylaxis Provides Continued Joint Protection in Severe Hemophilia A: Results of the Joint Outcome Continuation Study

Beth Boulden Warren, MD MS, Dianne Thornhill, PhD, Jill Stein, MD, Michael Fadell, MD, Sharon Funk, DPT, Heidi D. Lane, DPT, Carolyn M. Bennett, MD MSc, Amy Shapiro, Michael Recht, MD PhD, Marilyn J Manco-Johnson, MD

Blood (2018) 132 (Supplement 1): 382.

https://doi.org/10.1182/blood-2018-99-117413

Published: 2018

NARROW

Pharmacokinetics of Extended Half-Life Factor VIII Products By myPKFiT R Is Useful for Personalized Treatment in Children with Severe Hemophilia a

Quantitative Measurements of Hemophilic Joint Tissues By Point-of-Care Musculoskeletal Ultrasound Are Associated with Clinical and Functional Joint Outcome Parameters

Correcting Rare Blood Disorders Using Coagulation Factors Produced In Vivo By Shielded Living Therapeutics TM Products

Cost-Effectiveness Model of Recombinant FVIII Versus Emicizumab Treatment of Patients With Severe Hemophilia A Without Inhibitors

Prophylactic Treatment in People with Severe Hemophilia B in the US: An Analysis of Real-World Healthcare System Costs and Clinical Outcomes

Correlations between von Willebrand Factor Antigen Levels and Factor VIII Pharmacokinetics Are Similar across Different FVIII Products in Patients with Severe Hemophilia A

Non-Canonical MYD88/TIRAP-Dependent Anti-Inflammatory Function of Pro-Coagulant Factor VIII

Combined Point of Care Tools Are Able to Improve Treatment Adherence and Health-Related Quality of Life in Patients with Severe Hemophilia: An Observational Prospective Study

EPCR Deficiency Prevents Development of Hemophilic Arthropathy

Clinical Study to Investigate the Efficacy and Safety of Wilate during Prophylaxis in Previously Treated Patients with Von Willebrand Disease (VWD)

Characteristics of Hemophilia A Patients Treated with Emicizumab: an Early View using Claims Database Analysis

Innate Immune Mechanism of Hemarthrosis in Hemophilia-a Mice

Low-Grade Inflammation in Hemophilia

Estimating the Burden of Intracranial Hemorrhage in Persons with Hemophilia A using Administrative Claims Data

New therapies for hemophilia

Thrombin Generation As a Promising Biomarker for the Prediction of Bleeding Phenotype in Patients with Non-Severe Hemophilia

Adding Slow Release Tetracosactide Acetate to Eltrombopag Improves Haematological Response in ITP Patients with Platelet-Count Fluctuation

Changing the Paradigm in Hemophilia Care: Extended Half-Life Products (rFVIIIFc and rFIXFc)

Surveillance of Hemophilia in Indiana: A Preliminary Report

Early Prophylaxis Provides Continued Joint Protection in Severe Hemophilia A: Results of the Joint Outcome Continuation Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only